Lynovex® (NM001) is a first-in-class orphan drug candidate for cystic fibrosis, an inherited life-limiting disease affecting around 70,000 individuals worldwide. NovaBiotics is developing two formulations, Lynovex Oral for CF exacerbations, and Lynovex Inhaled for chronic CF therapy.
Lynovex is a novel, highly differentiated therapy for the treatment of CF-associated lung disease, with a unique multi-action; breakdown of the excessive mucus produced by the lining of the airways in patients, killing of the bacteria responsible for the recurrent respiratory infections and disrupting the biofilms in which they colonise. Lynovex also potentiates the activity of standard of care antibiotics used in CF patients and is initially intended for use alongside existing therapies to treat all disease genotypes. Lynovex is not a mutation-specific CFTR-targeting intervention.
NovaBiotics has established a strong IP position, with granted and pending global patents providing exclusivity in the use of cysteamine, the active agent in Lynovex, for CF. Orphan drug designation has been granted by the FDA (in the United States) and COMP (in Europe) for Lynovex in the treatment of CF. The Lynovex development program is supported by the Cystic Fibrosis Trust.
Lynovex in oral (hard gel capsule) form successfully completed a phase IIa clinical study in 2014/15, demonstrating its tolerability, safety and utility in adult CF patients with stable disease. The first phase of the global, pre-registration CARE-CF clinical trials for oral Lynovex in acute infectious CF exacerbations is now underway. See https://clinicaltrials.gov/show/NCT03000348 and Eudra CT 2015-004986-99. To learn more, please visit www.lynovex.com.
The unique multi-action properties of Lynovex have been demonstrated in in vitro & in vivo studies, as well as an ex vivo sputum study of CF patients. Preclinical studies are currently underway for inhaled Lynovex and NovaBiotics intends to initiate a proof-of-concept clinical study for inhaled Lynovex Inhaled in 2017/18.
Lynovex in hard gel capsule form should not be confused with other medicines also containing cysteamine for use in the metabolic disease, cystinosis. The mechanism of action, dose, dose frequency and duration of treatment for both conditions with these medicines is very different. Cysteamine’s tolerability and safety has only been evidenced thus far in adult CF patients when used as an acute therapy (e.g. per the CARE-CF-1 study, for 14 days).
AB21 9TR, UK
Tel: +44 (0)1224 711377
9121 Anson Way,
North Carolina 27615, US
Tel: +1 919 578 4216
Fax: +1 919 573 9409